Jacob Fleming Group is proud to announce a Pharma Sales Week in Brussels

21-22 October, 2008 - Pharma Sales Training & Development Conference
23-24 October, 2008 - Pharma Sales Technology & Customer Excellence
Successful Pharma companies understand, how to effectively engage and interact with the customers through the new e-health technologies.The sales reps, who possess an understanding of utilizing the new interactive tools, will be in a stronger position to meet the growing demands of the customers.

As the age of primary care blockbusters draws to close, and market is becoming more & more generic driven, a shift towards secondary care is becoming essential. Sales reps must now embrace internet technologies to improve influence and efficacy by supplementing traditional sales and marketing practices with eHealth applications.Reveal, how to adapt sales models and utilize the new technologies. Boost your sales and develop long-term customer relationships through CRM systems.

This event will bring together the experts from the pharmaceutical industry to benchmark their experiences in achieving sales force excellence.

Key speakers:

  • Vice President Global Sales Force Systems, GlaxoSmithKline, Poland
  • European Sales Force Effectiveness Director, Takeda, Italy
  • Senior Vice President Sales & Marketing, Actelion, USA
  • VP – Director of Global Operations, Astellas, Canada
  • Business Unit Director CNS, UCB Group, Italy
  • Lean Six Sigma Black Belt Sales & Marketing, Eli Lilly, Switzerland

Key topics:

  • Achieving Sales Force Excellence
  • Give your sales force the tools they need to succeed
  • Case studies on integrating CRM systems at local vs global level
  • Exploring the best sales & marketing practices to enhance sales force performance
  • Benchmarking the sales force models in Primary Care vs Secondary Care
  • Optimizing the sales forces
  • Keeping the pace with the sales force evolution

Who should attend:
Vice Presidents, Senior Executives, Heads, Directors and Managers of: Sales & Marketing, Sales Force, Field Force, Sales & Marketing Systems, Patient Relationship Marketing, CRM, E-Business, E-Marketing, E-Communication, Business Unit Directors, Product Managers, Sales Analysts, Key Account Management, Primay Care, Secondary Care, Hospital Operations, Managed Care Marketing, Disease Management, Communications, Consumer Marketing, General Managers

For further information, please visit:
http://www.jacobfleming.com/conferences/life-science/
5th-annual-pharma-sales-force-effectiveness

About Jacob Fleming Group
Jacob Fleming Group is one of the world's leading business intelligence companies producing business-to-business conferences which consists of current research, market trends, technological developments and applications. Our market-led intelligence allows our customers to make informed decisions for maximum bottom-line impact.

Jacob Fleming offices in Bratislava (Slovakia), Prague (Czech republic), Budapest (Hungary), Barcelona (Spain), Dubai (UAE) and Cleveland (USA) specialize in organizing prestigious international conferences for Europe and GCC region, providing groundbreaking strategies and proven technical expertise in both business functional areas and vertical markets through energy, finance, media, pharmaceutical and telecom sectors. For more information, visit www.jacobfleming.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...